Australia's largest stock trading and investment forum Australia's #1 stock forum

IAP

Click for more information

0.00%

$1.90 irongate group

Ann: IAP receives revised indicative proposal from 360 Capital, page-5

First 5 Last

Share
Profile

Follow
MJS

2,280 Posts.

26

12/01/22

10:22

Post #: 58796183
Share

Originally posted by eigenvalue: ↑

In the last investor presentation, IAP specified net asset value per share equal to $1.60. Such a value seems about right, if the fast growing asset management business is valued at circa 3% of AUM (reasonable).

360 Capital Group's revised offer is for $1.72, so, a 7.5% premium above NAV per share and the current trading share price. It's almost an insult for a well run company. Also, if long-term investors are bought out, they'll have deferred tax liabilities to pay, so the premium is almost non-existent in actuality.

360 Capital Group continues to make reference to the IAP share price back in October: that's entirely irrelevant, as the whole REIT market has moved upwardly appreciably since then (about 8%).

Note to 360 Capital Group: think 35 to 40% premium to NAV and you may get somewhere.

Note to IAP: TOT is trading at a 22% discount to last published NTA; they own a lot of your shares: buy them (out).

Expand

That might all be true. However if it's taken 360 Capital to buy much lower and bring some value recognition to the business maybe management isn't all you think they are ‍♂️

IAP Price at posting: $1.69 Sentiment: None Disclosure: Not Held
Upvote

0 Great analysis

Reply

Top Stories

BCI

BCI reaches close of funding facility for salt-first part of Mardie project

BUX

Buxton projects new graphite province discovery at WA Narryer play

SLS

Solstice Minerals to ramp up drilling campaign at Yarri Gold Project

COD

Coda Minerals (ASX:COD) enters rights issue to further exploration in South Australia

WCN

White Cliff jumps 24% on 'bonanza grade' copper rock chips at Rae project, Canada

Week 40 Wrap: China's nonsensical stimmy hype wanes (shocking!); HotCopper's picks; oil & inflation

RCE

Recce eyes Indonesia for novel anti-infective as Indo-Aus ties grow stronger

CKA

Cokal upgrades infrastructure for BBM ramp-up in Indonesia

ACW

Actinogen Medical ramps up Alzheimer’s treatment trials, targeting fast-track global approvals

NTI

Neurotech knocked back by FDA as agency declares target condition not rare enough for special status

There are more pages in this discussion • 2 more messages in this thread...

First 5 Last

Add IAP (ASX) to my watchlist